Teriparatide Dr. Reddy's
Teriparatide biosimilar developed by Dr. Reddy's Laboratories. Reference product Forsteo (Forteo in the United States).
About Teriparatide Dr. Reddy's
Teriparatide Dr. Reddy's is Dr. Reddy's teriparatide for the United Kingdom, licensed as a pre-filled pen under the company's name rather than a brand. It adds to the company's rituximab, approved in Europe and the United States.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom · Teriparatide Dr. Reddy's
Medicines and Healthcare products Regulatory AgencyApprovedJapan
Not listed by PMDA.
Canada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Teriparatide Dr. Reddy's holds an approval, these are the other teriparatide biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| MHRA | 6 | Gedeon Richter (Terrosa / Movymia), Intas Pharmaceuticals (Sondelbay / Intas teriparatide), Not stated in the MHRA list (Teriparatide Ambio Pharma), Strides Pharma (Kauliv), Sun Pharmaceutical Industries (Teriparatide Sun), Teva (Teriparatide Teva) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Dr. Reddy's Laboratories: Dr. Reddy's bevacizumab, Dr. Reddy's darbepoetin alfa, Dr. Reddy's pegfilgrastim, Dr. Reddy's trastuzumab, Zimrixby / Ituxredi.
Chronology
Sources
S023MHRA Products, substance lists of licensed medicines (products.mhra.gov.uk) Primary (regulator)
Planning teriparatide biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant